Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer

Hepatocellular Carcinoma Clinical Trial

Official title:

A Phase I Study of High-Dose Oral Vitamin D for the Prevention of Hepatocellular Carcinoma in Subjects With Cirrhosis

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01956864
• Other study ID #: IRB00047888
• Status: Withdrawn
• Phase: Phase 1
• First received: September 30, 2013
• Last updated: January 30, 2018
• Start date: September 2013
• Est. completion date: February 11, 2016

Study information

• Verified date: January 2018
• Source: Johns Hopkins University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and tolerability of a high dose of vitamin D (VD) in patients with cirrhosis. The investigator hypothesizes that high dose VD will be safe and well-tolerated in adults with cirrhosis, and will inhibit the inflammatory and proliferative events that cause progression of cirrhosis to hepatocellular carcinoma.

Description:

This study will be done in two phases. The first phase is being done to find the highest dose of VD that can be tolerated, in other words taken without causing severe side effects. The second phase is a 6 month treatment with the dose determined to be safe in the first phase, to investigate general health benefits and the potential to reduce the development of Hepatocellular carcinoma (HCC), also known as liver cancer. Improvement of general health will be determined by interviews with patients, markers in the blood for response to VD, bone remodeling, inflammation, and evidence of HCC on routine imaging.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: February 11, 2016
• Est. primary completion date: February 11, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. All subjects between the ages of 18 and 75 with cirrhosis of any etiology followed at the Georgetown Transplant Institute, Washington, DC, will be offered entry into this study. The diagnosis of cirrhosis will be based on clinical, imaging or histological studies.

2. No evidence of HCC on entry imaging study ( if liver nodules are present, these should be classified as LIRADS 1-3 only).

3. Model for End Stage Liver Disease (MELD) score under 22 (a MELD score over 22 would predict a 3 month mortality rate of approximately 20%).

4. Not currently participating in another intervention study.

5. Not pregnant or lactating, and willing to use effective contraception during study period.

6. Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.

7. Ability to provide written informed consent according to national/local regulations

Exclusion Criteria:

1. Any diagnosis of kidney stones

2. A diagnosis of granulomatous diseases (e.g., sarcoidosis), active chronic fungal or mycobacterial infections (e.g., tuberculosis, histoplasmosis, coccidioidomycosis, blastomycosis, berylliosis, or Wegener's granulomatosis) in the past 6 months

3. A diagnosis of hyperparathyroidism or other serious disturbance of calcium metabolism in the past 5 years

4. A diagnosis of severe kidney disease, e.g., chronic renal failure, in the past 6 months

5. A diagnosis of unexplained hypercalcemia in the past 6 months

6. Any diagnosis of osteoporosis with physician recommendation for treatment of low bone mass

7. A diagnosis of two or more low trauma fractures in the past 6 months

8. A diagnosis of a medical condition requiring treatment with VD (e.g., osteomalacia) in the past 6 months

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Cirrhosis
• Fibrosis
• Hepatocellular Carcinoma
• Liver Cirrhosis

Intervention

Drug:
• Vitamin D
Doses of vitamin D will be increased from a baseline dose to the maximum tolerated dose. There could therefore be up to 5 possible doses of Vitamin D. Once the maximum tolerated dose of vitamin D has been determined, patients will follow a regimen on that dose for 6 months.

Locations

Country	Name	City	State
United States	Sibley Memorial Hospital /Johns Hopkins University	Washington	District of Columbia

Sponsors (2)

Lead Sponsor	Collaborator
Johns Hopkins University	M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants on high dose Vitamin D with adverse events		after 1 year
Secondary	Changes in the expression of serum and imaging biomarkers		After 6 months on vitamin D regimen